Robert Browne
Director of Finance/CFO at Viron Therapeutics, Inc.
Network origin in Robert Browne first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Robert Browne via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Cita NeuroPharmaceuticals, Inc.
 Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Biotechnology | Chairman | |
| Resolution Pharmaceuticals, Inc. | Chief Executive Officer | ||
Vaxis Therapeutics Corp
 Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Part of DMK Pharmaceuticals Corp., Vaxis Therapeutics Corp manufactures and researches pharmaceutical products. The company is based in Kingston, Canada. Vaxis Therapeutics was acquired by Cellegy Pharmaceuticals, Inc. on November 29, 2001 for $4 million. | Pharmaceuticals: Major | Chief Executive Officer | |
| TELESTA THERAPEUTICS INC | Pharmaceuticals: Other | Chairman | |
| Remedies Health Care Services, Inc. | Founder | ||
PlantForm Corp.
 PlantForm Corp. Pharmaceuticals: MajorHealth Technology PlantForm Corp. engages in a biopharmaceutical company. It focuses on the development and production of ntibody and protein drugs using manufacturing platform. The firm’s vivoXPRESS technology uses genetically modified tobacco plants to produce biopharmaceuticals in fully contained greenhouse environments. The company was founded by J. Christopher Hall, Mark Goldberg, Don Stewart, and Ronald G. Hosking in 2008 and is headquartered in Toronto, Canada. | Pharmaceuticals: Major | Director/Board Member | |
| University of Alberta | College/University | Doctorate Degree |
Statistics
International
| Canada | 13 |
Sectoral
| Health Technology | 10 |
| Consumer Services | 2 |
Operational
| Chief Executive Officer | 5 |
| Chairman | 5 |
| Director/Board Member | 4 |
| President | 4 |
| Founder | 2 |
Most connected contacts
| Insiders | |
|---|---|
| James Moodie Rae | 12 |
| Colin Macaulay | 2 |
- Stock Market
- Insiders
- Robert Browne
- Company connections
